Discounted Cash Flow (DCF) Analysis Levered
Krystal Biotech, Inc. (KRYS)
$117.9
+2.22 (+1.92%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 1.03 | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -9.45 | - | - | - | - | - | - | - | - | - |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -2.23 | - | - | - | - | - | - | - | - | - |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -11.68 | - | - | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
Share price | $ 117.9 |
---|---|
Beta | 0.827 |
Diluted Shares Outstanding | 25.49 |
Cost of Debt | |
Tax Rate | 0.00 |
After-tax Cost of Debt | 58.45% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 8.503 |
Total Debt | 8.93 |
Total Equity | 3,005.47 |
Total Capital | 3,014.41 |
Debt Weighting | 0.30 |
Equity Weighting | 99.70 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 1.03 | - | - | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -9.45 | - | - | - | - | - | - | - | - | - |
Capital Expenditure | -2.23 | - | - | - | - | - | - | - | - | - |
Free Cash Flow | -11.68 | - | - | - | - | - | - | - | - | - |
WACC | ||||||||||
PV LFCF | - | - | - | - | - | - | - | - | - | |
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 8.65 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -152.97 |
Equity Value | - |
Shares Outstanding | 25.49 |
Equity Value Per Share | - |